AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

ITOS(Quitar la ciudad)

iTeos Therapeutics·NASDAQ
--
--(--)

iTeos Therapeutics (ITOS) Stock Statistics, Valuation & Financial Metrics

Total Valuation

iTeos Therapeutics market cap is -- and enterprise value is --.

Share Statistics

iTeos Therapeutics has 44.21M shares outstanding, with a free float of 42.71M.

Valuation Ratios

iTeos Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.

Solvency

iTeos Therapeutics debt-to-equity ratio is -- and debt-to-assets ratio is 0.21.

Liquidity

iTeos Therapeutics's current ratio is 7.53, quick ratio is 7.53, and cash ratio is --, showing its short-term liquidity position.

Return on Capital

iTeos Therapeutics's ROE is --, ROA is --, and ROIC is --, showing its return on capital profile.

Profitability

iTeos Therapeutics gross margin is --, operating margin is --, and net margin is --.

Cost Structure

iTeos Therapeutics spends -- of revenue on R&D and -- on SG&A.

Operating Efficiency

iTeos Therapeutics's asset turnover is --, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.

Revenue Per Employee
202.31K
Profits Per Employee
-776.96K

Income Statement

iTeos Therapeutics's revenue is --, gross profit is --, net income is --, and EBITDA is --.

Balance Sheet

iTeos Therapeutics's total debt is --, net debt is --, total equity is --, and cash is --.

Cash Flow Statement

iTeos Therapeutics's operating cash flow is -108.06M, free cash flow is -108.69M, and CapEx is -630.00K.

Dividends & Yields

iTeos Therapeutics dividend yield is --, with a payout ratio of -- and dividend per share of --.

Analyst Rating

iTeos Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.

Analyst Rating
Unrate

Company Info

A clinical-stage biopharmaceutical company that developing immuno-oncology therapeutics for cancer

Listing Date
2020-07-24

Per Share Metrics

iTeos Therapeutics's EPS is --, book value per share is --, and free cash flow per share is --.